Theralase Technologies Inc. (TSX-V: TLT) announced today the successful results of preclinical studies (in-vitro and in-vivo) demonstrating significant destruction of various brain and colon cancer cell lines. The new proprietary Theralase treatment sharply delayed the tumour progression, when attacked by the Theralase patented light activated Photo Dynamic Compounds (PDCs), signifying a new and broadly promising approach to cancer treatment. When treated with the Theralase PDCs, cancerous mice survived cancer-free for more than 100 days post-treatment, a highly significant milestone.

1. Press Release
Theralase Photo Dynamic Compounds Destroy Cancer
Toronto, Ontario – October 22, 2012, Theralase Technologies Inc. (TSX-V: TLT) announced today the
successful results of preclinical studies (in-vitro and in-vivo) demonstrating significant destruction of
various brain and colon cancer cell lines. The new proprietary Theralase treatment sharply delayed the
tumour progression, when attacked by the Theralase patented light activated Photo Dynamic
Compounds (PDCs), signifying a new and broadly promising approach to cancer treatment. When
treated with the Theralase PDCs, cancerous mice survived cancer-free for more than 100 days post-
treatment, a highly significant milestone.
The scientific data supporting this breakthrough was presented and well received recently at the 9th
International Symposium of Photodynamic Therapy and Photodiagnosis in Clinical Practice held in
Brixen, Italy. The Theralase presentation was made by Dr. Lothar Lilge, Senior Scientist, Ontario Cancer
Institute / Princess Margaret Cancer Centre, University Health Network (UHN) and confirms the
significance of the successful research conducted by Theralase in collaboration with UHN scientists,
validating this scientific work on the international stage.
Dr. Lothar Lilge stated that, "These preclinical results demonstrate that the Theralase Photo Dynamic
Compounds appear to be highly effective (100% cancer cell kill) when used to destroy various cancer
cell lines in-vitro; specifically, brain glioma (U-87 and F-98) and in-vivo; specifically, colon cancer (CT-
26WT), in the treatment of subcutaneous cancer tumours in Balb/c mice. Mice enrolled in the study,
presented with subcutaneous cancerous lesions of approximately 6 mm in size prior to treatment,
which is standard for these preclinical models. The statistically significant improvement in survival
times make these results even more encouraging, as a number of mice are still alive today living cancer
free, 100 days post treatment. Moreover, we believe that tested PDCs may have potential for Type I
(oxygen independent) PDT effect; hence, their clinical use would represent a significant gain in cancer
therapy.”
Dr. Arkady Mandel, Chief Scientific Officer at Theralase Inc. stated that, "We were delighted with the
extremely promising results of our latest cancer studies, which demonstrate significant anticancer
destruction of Theralase’s PDCs in all tested in-vitro studies and in difficult to treat in-vivo cancer
models, without significant optimization. With optimization, the ability of the Theralase PDCs to target
and destroy cancerous tumours could be even more enhanced. There are a number of obvious
advantages for the use of Theralase’s PDCs in the destruction of cancer that have been established by
this body of work, such as: the Photo Dynamic Therapy (PDT) effect has been achieved at lower
concentrations compared to aminolevulinic acid, also known as ALA (ALA is a currently approved FDA
PDC) and with lower dark toxicity (PDC alone with no light) compared to methylene blue (another
PDC), the Theralase PDCs have potential for Type I (oxygen independent) PDT effect and lastly were
able to induce tumour necrosis (cell death) in mice that allowed prolonged survival, cancer free, in
excess of 100 days of observation. New evidence from experimental and clinical studies increasingly
points to a lack of oxygen content or hypoxia in solid tumours to be strongly associated with tumour
propagation, malignant progression and resistance to therapy and it has thus become one of the
central issues in tumour physiology and cancer treatment. Therefore, with the latest scientific data in

2. Press Release
hand, Theralase’s PDT has the potential to become more expeditiously integrated into the mainstream
of cancer treatment.”
Roger Dumoulin-White, President and CEO of Theralase stated, “This new research extends the
opportunity of Theralase’s patented PDC technology to have a successful impact on two additional
devastating forms of cancer; specifically, brain and colon cancer. Our research has demonstrated a kill
rate of effectively 100% in specific human brain and colon cancer cells lines. With the high mouse
survival rate, which is approximately equivalent to 11 years “cancer free” in humans, being observed in
this study, these results lay the groundwork for further preclinical work for these specific cancers. If the
preclinical work is proven successful, this would lead to human clinical trials as early as 2013. Theralase
plans to aggressively pursue commercialization of its ground-breaking PDT technology through the FDA
regulatory approval process and is on track to commence FDA Phase 1 human clinical trials as early as
this time next year. Theralase plans to continue its research and development at an accelerated pace
to optimize and expand its growing patent portfolio of PDCs that are able to destroy a variety of life
threatening cancers.”
About Theralase Technologies Inc.:
Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented,
superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase
technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural
muscular skeletal conditions and wound healing. Theralase is currently developing patented Photo
Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when
light activated by Theralase’s proprietary and patented laser technology.
For further information please visit www.theralase.com , regulatory filings may be viewed by visiting
www.sedar.com.
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to
update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts
responsibility for the adequacy or accuracy of this release.
For More Information
Roger Dumoulin-White
President & CEO,
416-447-8455 ext. 225
rwhite@theralase.com
Kristina Hachey
Chief Financial Officer
416-447-8455 ext. 224
khachey@theralase.com
Arkady Mandel

3. Press Release
Chief Scientific Officer
416-447-8455 ext. 242
amandel@theralase.com
Greg Bewsh
Director of Investor Relations,
416-447-8455 ext. 262
gbewsh@theralase.com